Beamr video compression achieves up to 50% improvement for AVs
Patrick Lin, Chief Business and Strategy Officer at Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), recently acquired 43,500 shares of the company’s common stock. The shares were purchased at a price of $0.7975 each, totaling approximately $34,691. The purchase comes as the stock trades near its 52-week low of $0.47, with InvestingPro analysis indicating the shares are currently in oversold territory. This transaction was conducted on January 27, 2025, and the shares are owned indirectly through the Lin Family Trust. Following this transaction, Lin holds 43,500 shares indirectly and 29,059 shares directly. The micro-cap company, currently valued at $1.84 million, has seen its stock decline nearly 79% over the past year. InvestingPro subscribers can access 14 additional technical and fundamental insights about PCSA, including detailed Fair Value analysis and financial health metrics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.